Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth

Table 3 Univariate and multivariate analysis of tuftelin 1 in the prognosis of hepatocellular carcinoma

Group	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
TUFT1 expression, high vs low	3.026	1.927-4.752	< 0.001	1.743	1.044-2.910	0.034
AFP (ng/mL), ≥ 20 vs < 20	1.866	1.066-3.266	0.027	1.482	0.835-2.630	0.178
HBsAg, pos. vs neg.	1.495	0.652-3.431	0.339
HBeAg, pos. vs neg.	1.670	1.084-2.574	0.019	1.070	0.659-1.739	0.784
Tumor size (cm), ≥ 3 vs < 3	3.680	1.837-7.370	< 0.001	2.235	1.043-4.485	0.039
Differentiation degree, Poor vs well-med.	1.642	0.869-3.100	0.123
Vascular invasion, with vs without	3.297	2.133-5.094	< 0.001	2.018	1.186-3.434	0.010
Ascites, with vs without	2.592	1.648-4.076	< 0.001	1.929	1.177-3.161	0.009
TNM staging, III-IV vs I-II	2.411	1.532-3.796	< 0.001	1.110	0.614-2.005	0.731

AFP: Alpha-fetoprotein; HBeAg: hepatitis B virus e antigen; HBsAg: hepatitis B virus surface antigen; HR: Hazard ratio; Neg: Negative expression; Pos: Positive expression; TNM: Tumor-node-metastasis.